| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Theravance Biopharma, Inc. (TBPH) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. TBPH is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.65M | $27.37M | - | |
| VP | 355.3K | $5.89M | - | |
| CFO | 336.8K | $5.58M | - | |
| VP | 242.4K | $4.02M | -13,314 | |
| VP | 201.0K | $3.33M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 14, 2023 | Graham Richard A71 | SVP, Research &Development | Sell | 2,322 | $10.69 | $24,822.18 | -0.7% | -5.6% | -17.6% | |
| Jun 8, 2023 | Farnum Rhonda52 | SVP, Comm &Medical Affairs | Sell | 1,790 | $11.13 | $19,922.70 | -0.5% | -14.3% | -21.3% | |
| May 15, 2023 | Graham Richard A71 | SVP, Research &Development | Sell | 2,322 | $11.26 | $26,145.72 | -0.6% | -10.6% | -16.6% | |
| Apr 14, 2023 | Graham Richard A71 | SVP, Research &Development | Sell | 2,323 | $11.88 | $27,597.24 | -0.6% | -17.4% | -19.4% | |
| Mar 14, 2023 | Graham Richard A71 | SVP, Research &Development | Sell | 2,323 | $10.32 | $23,973.36 | -0.6% | -0.7% | -17.1% | |
| Mar 9, 2023 | Farnum Rhonda52 | SVP, Comm &Medical Affairs | Sell | 4,000 | $10.20 | $40,800.00 | -1.1% | +9.0% | -15.9% | |
| Mar 6, 2023 | Graham Richard A71 | SVP, Research &Development | Sell | 2,323 | $10.05 | $23,346.15 | -0.6% | +9.8% | -14.6% | |
| Dec 14, 2022 | Winningham Rick E64 | Chief Executive Officer | Sell | 50,000 | $11.19 | $559,500.00 | -3.6% | -5.4% | -1.8% | |
| Dec 1, 2022 | Graham Richard A71 | SVP, Research &Development | Sell | 2,084 | $10.73 | $22,361.32 | -0.7% | -7.0% | -1.4% | |
| Nov 18, 2022 | Hindman Andrew A. | SVP, Chief Financial Officer | Sell | 65,000 | $11.02 | $716,241.50 | -13.7% | -5.9% | -3.7% |